NASDAQ:AXGN - AxoGen Stock Price, Forecast & News

AxoGen trades on the NASDAQ under the ticker symbol "AXGN."

AxoGen, Inc (NASDAQ:AXGN) issued its earnings results on Wednesday, November, 6th. The medical equipment provider reported ($0.13) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.17) by $0.04. The medical equipment provider earned $28.56 million during the quarter, compared to the consensus estimate of $28.10 million. AxoGen had a negative return on equity of 17.82% and a negative net margin of 26.79%. View AxoGen's Earnings History.

AxoGen is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for AxoGen.

AxoGen updated its FY 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $106.6 million, compared to the consensus revenue estimate of $107.76 million.

5 Wall Street analysts have issued 1 year price objectives for AxoGen's stock. Their forecasts range from $21.00 to $30.00. On average, they expect AxoGen's share price to reach $25.00 in the next year. This suggests a possible upside of 104.2% from the stock's current price. View Analyst Price Targets for AxoGen.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AxoGen.

News headlines about AXGN stock have trended extremely negative this week, according to InfoTrie. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. AxoGen earned a daily sentiment score of -4.5 on InfoTrie's scale. They also gave news coverage about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for AxoGen.

AxoGen saw a increase in short interest in December. As of December 13th, there was short interest totalling 1,950,000 shares, an increase of 10.2% from the November 28th total of 1,770,000 shares. Based on an average trading volume of 364,600 shares, the days-to-cover ratio is presently 5.3 days. Approximately 5.5% of the shares of the stock are sold short. View AxoGen's Current Options Chain.

Some companies that are related to AxoGen include InMode (INMD), Natus Medical (NTUS), Cutera (CUTR), TransMedics Group (TMDX), Stereotaxis (STXS), Zynex (ZYXI), Semler Scientific (SMLR), BioLife Solutions (BLFS), Viewray (VRAY), Soleno Therapeutics (SLNO), Rockwell Medical (RMTI), Fonar (FONR), BioSig Technologies (BSGM), Edap Tms (EDAP) and Second Sight Medical Products (EYES).

Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Intelsat (I), Exelixis (EXEL), Xilinx (XLNX), Advanced Micro Devices (AMD), Micron Technology (MU), Bank of America (BAC), Corbus Pharmaceuticals (CRBP), Crispr Therapeutics (CRSP), Amarin (AMRN) and NVIDIA (NVDA).

AxoGen's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Peregrine Capital Management LLC (1.43%), Pennsylvania Trust Co (0.51%) and Exchange Traded Concepts LLC (0.01%). Company insiders that own AxoGen stock include Amy Mcbride Wendell, Daniel Pietrzak, David K Hansen, Gregory Gene Freitag, Isabelle Billet, Jamie Mark Grooms, Karen L Zaderej, Michael Patrick Donovan, Quentin S Blackford and Shawn F Mccarrey. View Institutional Ownership Trends for AxoGen.

AXGN stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC and Pennsylvania Trust Co. Company insiders that have sold AxoGen company stock in the last year include David K Hansen and Michael Patrick Donovan. View Insider Buying and Selling for AxoGen.

AXGN stock was acquired by a variety of institutional investors in the last quarter, including Exchange Traded Concepts LLC. Company insiders that have bought AxoGen stock in the last two years include Amy Mcbride Wendell, Daniel Pietrzak, Isabelle Billet, Karen L Zaderej and Quentin S Blackford. View Insider Buying and Selling for AxoGen.

Shares of AXGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AXGN stock can currently be purchased for approximately $12.24.

AxoGen has a market capitalization of $483.11 million and generates $83.94 million in revenue each year. The medical equipment provider earns $-22,400,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. View Additional Information About AxoGen.

The official website for AxoGen is http://www.axogeninc.com/.

AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The medical equipment provider can be reached via phone at 386-462-6800 or via email at [email protected]